SAN DIEGO--(BUSINESS WIRE)--Vaxiion Therapeutics, Inc. today announced the issuance of U.S. patent no. 7,183,105 from the U.S. Patent and Trademark Office. The patent is entitled, “Eubacterial minicells and their use as vectors for nucleic acid delivery and expression,” and broadly relates to compositions and methods of using Vaxiion’s proprietary minicells as vaccine delivery vehicles.
